An educational index built around scientific questions, evidence levels, experimental models, and careful interpretation rather than benefit-driven claims.
Recent publications from Europe PMC, linked to their original records. Topic overviews are based on publication metadata; preprints are labeled separately.
Nature Communications published StriMap, a framework integrating physicochemical, sequence-context, and structural features to model TCR–peptide–HLA recognition.
Read at Nature Communications →Eli Lilly announced that Phase 3 retatrutide results from TRIUMPH-2 will be presented at EASD 2026. The compound remains investigational.
Read at Eli Lilly →Nature Biotechnology reported a nanopore system that identified peptides, amino acids, nucleotides, and saccharides with machine-learning-assisted classification.
Read at Nature Biotechnology →Scientific Data published more than 10,000 coarse-grained simulation trajectories covering 3,855 cyclic-peptide sequences and membrane interactions.
Read at Scientific Data →Updated September 28, 2026. Source summaries are educational and do not constitute medical advice or product claims.
A practical guide to batch identity, analytical methods, result units and the questions a peptide certificate of analysis can—and cannot—answer.
Read the overview →Learn how separation and mass measurement answer different analytical questions, with a primary example of peptide-fragment characterization.
Read the overview →A guide to identifying study models, endpoints and evidence limits before interpreting peptide research headlines.
Read the overview →A source-linked introduction to retatrutide receptor biology, the published phase 2 trial, and the limits of applying clinical findings to research materials.
Read the overview →An educational overview of BPC-157 tendon-model research, the questions those experiments address, and why laboratory findings require careful interpretation.
Read the overview →Understand the distinction between GHK and GHK-Cu, a primary fibroblast-culture study, and the limits of translating cellular findings into product claims.
Read the overview →A source-linked look at TB-500 naming, a characterized thymosin beta-4 fragment, and why sequence confirmation comes before comparing studies.
Read the overview →Explore the original MOTS-c publication, mitochondrial peptide signaling, and how to distinguish experimental metabolic findings from human outcomes.
Read the overview →A research-focused introduction to tesamorelin, GHRH signaling, and the difference between approved product documentation and a research-material listing.
Read the overview →